Acute myeloid leukemia, adult

Active Research Protocols

  1. 01-C-0125 – Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
  2. 04-C-0102 – Hematologic Malignancy Biology Study
  3. 06-H-0248 – Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back
  4. 07-H-0136 – Selective Depletion of Alloreacting T Cells Using a Photodepletion Technique to Prevent GVHD after HLA-Matched Peripheral Blood Stem Cell Transplantation for Subjects with Hematologic Malignancies
  5. 08-C-0051 – A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
  6. 09-C-0096 – Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for Patients with GATA2 Mutations
  7. 09-H-0087 – Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation
  8. 11-C-0125 – Relapsed Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation: Screening, Disease Characterization and Natural History
  9. 11-C-0136 – Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging Evaluation
  10. 12-H-0146 – Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia
  11. 13-C-0132 – Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC syndrome
  12. 99-H-0046 – Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation Followed by T-Cell Add-Back for Hematological Malignancies - Role of Cyclosporine
  13. 99-H-0050 – Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014